Trial Profile
Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF: a Pilot Study - KINETIK (KIdNEy Transplant bIKtarvy) IMEA 064
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Calcineurin inhibitors; MTOR protein inhibitors
- Indications HIV-1 infections; Renal failure
- Focus Pharmacokinetics
- Acronyms KINETIK
- 23 May 2023 Planned End Date changed from 30 Oct 2023 to 1 Jul 2024.
- 23 May 2023 Planned primary completion date changed from 30 Oct 2022 to 1 Jul 2023.
- 23 May 2023 Status changed from not yet recruiting to active, no longer recruiting.